Ideaya Biosciences (IDYA) announced it has entered into a clinical study collaboration and supply agreement with Gilead Sciences (GILD) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead’s sacituzumab-govitecan-hziy, a Trop-2 directed antibody-drug conjugate, or ADC, in a Phase 1 clinical trial. Under the clinical study collaboration and supply agreement, Gilead will provide drug supply to Ideaya, which will be the sponsor of the Phase 1 clinical combination trial. Ideaya and Gilead each retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $41 from $35 at JPMorgan
- Ideaya Biosciences to hold a virtual meeting
- Ideaya Biosciences price target lowered to $44 from $48 at Guggenheim
- Ideaya Biosciences price target raised to $40 from $35 at Oppenheimer
- Ideaya Biosciences reports Q3 EPS (46c), consensus (49c)